CD36在乳腺癌发病中的分子机制和治疗探索  

Molecular Mechanism and Therapeutic Exploration of CD36 in Breast Cancer

作　　者：付胜巧 姬倩 孙昕雨 浦希 吴玉婷 唐浩文 盛婉盈 王旭[1] FU Shengqiao;JI Qian;SUN Xinyu;PU Xi;WU Yuting;TANG Haowei;SHENG Wanying;WANG Xu(Department of Radiation Oncology Affiliated Hospital of Jiangsu University,Cancer Institute,Zhenjiang 212000,China;Department of Pulmonary Oncology,Zhongnan Hospital,Wuhan University,Wuhan 430000,China)

机构地区：[1]江苏大学附属医院放疗科,肿瘤研究院,镇江212000 [2]武汉大学中南医院肺肿瘤科,武汉430000

出　　处：《肿瘤防治研究》2024年第5期380-385,共6页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金面上项目(32170910);江苏省研究生科研与实践创新计划项目(KYCX22_3720)。

摘　　要：乳腺癌是全世界妇女癌症相关死亡的主要原因之一,严重威胁着全球女性的健康。目前虽部分乳腺癌患者的预后有所改善,但耐药的出现以及乳腺癌的转移和复发仍然是患者预后不良的主要原因。CD36是一种在多种细胞类型上表达的多配体跨膜糖蛋白。近年来,研究证实CD36可重塑癌细胞脂代谢,促进肿瘤相关巨噬细胞分化为M2型并招募到肿瘤组织,调控Treg、CD8+T、DC等免疫细胞功能,从而促进肿瘤发展。此外,CD36还与乳腺癌干细胞、肿瘤转移起始细胞和乳腺耐药细胞相关。因此,CD36可作为乳腺癌的一个重要潜在治疗靶点。Breast cancer is the most diagnosed cancer in women worldwide and the leading cause of most cancer-related deaths,posing a serious threat to women′s health worldwide.At present,although the prognosis of some patients with breast cancer has improved,the emergence of drug resistance and the metastasis and recurrence of breast cancer are still the main reasons for poor prognosis.CD36 is a multiligand transmembrane glycoprotein expressed on various cell types.In recent years,studies have confirmed that CD36 can reshape the lipid metabolism of cancer cells;promote the differentiation of tumor-related macrophages into M2 type and recruitment into tumor tissues;regulate the function of Treg cells,CD8+T cells,DCs,and other immune cells,and thus promote tumor development.In addition,CD36 is also associated with breast cancer stem cells,metastasis-initiating cells,and breast drug resistant cells.Therefore,CD36 could be an important potential therapeutic target for breast cancer.

关 键 词：乳腺癌 CD36分子 肿瘤代谢重塑 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]